Vaishali Pharma LtdQ3 FY23Pharmaceuticals & Biotechnology

Vaishali Pharma Ltd

Q3 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Revenue guidance

Category 3

→Vaishali Pharma targets INR 400-500 crores revenue in the next 3-5 years, with an annual growth rate of 18%-20%, possibly increasing slightly.
→They aim to maintain sustainable and improving EBITDA margins, with growth driven by formulations and nutraceutical verticals.
→Major focus remains on exports, especially in Africa, with plans expanding into Gulf, Latin America, Europe, and Southeast Asia.
→Strategic plans include acquiring a manufacturing facility within 2-3 years to support vertical integration and continued growth from the current asset-light model.
→Around 350 products currently registered, with 200 more in the pipeline, expected to launch over 2-3 years, supporting long-term growth.
→Large orders, such as the INR 600 crores tender, could accelerate revenue beyond base growth projections.
→Expansion strategies also involve participation in government tenders internationally, especially in African and European markets.

Category 3

→Vaishali Pharma targets revenue growth of INR 400-500 crores in the next 3-5 years, with an annual growth rate of 18%-20%, potentially increasing to 25% depending on market conditions.
→They anticipate sustaining or improving EBITDA margins, currently around 21%-23%, driven by higher-margin formulations and brand strength.
→Expansion plans include acquiring a manufacturing facility within 2-3 years to support vertical integration and increased capacity.
→The margin is expected to increase as brand volume grows, unlike typical trading where margin pressure occurs.
→Profitability is projected to improve with increased repeat orders and newer product launches, including 350 products registered and 200 in the pipeline.
→EPS growth aligns with revenue and margin improvements, with recent Q2 FY24 EPS at INR 1.61 and H1 FY24 EPS at INR 3.10, expecting upward momentum.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Vaishali Pharma Ltd and 1,400+ other companies.

→Currently, Vaishali Pharma Limited does not require additional capital or capacity for its growth plans.
→The company has made arrangements to address future needs without immediate capital infusion.
→There is no mention of any ongoing or planned fundraising through debt or equity in the near term.
→However, within the next 2-3 years, the company is considering acquiring a manufacturing facility, indicating potential future capital expenditure.
→No specific plans or timelines for fundraising related to this acquisition or other purposes were detailed.

Yes

→Vaishali Pharma has an order of at least INR 15 crores currently in the pipeline, which is already on hand.
→A significant export order worth INR 600 crores was received in February, but its execution is currently stuck due to advance payment and paperwork issues in the international market.
→The company maintains an annual growth rate target of 18%-20%, with expectations of minimal variation.
→Order booking for H2 FY24 is underway, and the company is monitoring progress closely, aiming for growth compared to previous years.
→Repeat orders and increased market expectations contribute to margin growth.
→Trade receivables are in cycle and realizable as per due dates, indicating stable order execution.
→The strategic plan includes aggressive tender submissions internationally (Africa, Europe) to expand order book in coming years.

Yes

→Vaishali Pharma is currently operating under an asset-light model and does not require immediate additional capital or capacity.
→Within the next 2-3 years, the company plans to acquire a manufacturing facility to enable vertical expansion.
→The acquisition of the manufacturing unit aligns with their strategy to meet growing demand and move beyond contract manufacturing.
→No significant near-term capex is planned, but inorganic growth through factory acquisition is anticipated within the 2-3 year timeframe.
→The company is actively involved in product registration and expanding its product pipeline to support growth.
→The strategic tie-up with Sankalp Life Care for nutraceutical marketing serves as an ongoing partnership to boost global reach without immediate capital investment.

How does Vaishali Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Vaishali Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Vaishali Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.